BNP Paribas Financial Markets
NRSN icon

BNP Paribas Financial Markets’s NeuroSense Therapeutics NRSN Stock Holding History

BNP Paribas Financial Markets’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,800
Closed -$12.9K – 5704
2025
Q2 		$12.9K Buy
+6,800
New +$9.85K ﹤0.01% 4779

Other funds holding NRSN

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

BNP Paribas Financial Markets's NRSN Position: Q3 2025 in Review

BNP Paribas Financial Markets sold out of NeuroSense Therapeutics (NRSN) in Q3 2025, closing a stake of 6,800 shares — an estimated $12.9K sold.

BNP Paribas Financial Markets first reported a position in NRSN in Q2 2025 and held it in 1 quarter. The position peaked at $12.9K in Q2 2025. 10 funds tracked by Wall St. Rank hold NRSN as of Q3 2025.

  • BNP Paribas Financial Markets reported no remaining NeuroSense Therapeutics position as of Q3 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 6,800 NeuroSense Therapeutics shares in Q3 2025, an estimated $12.9K.
  • BNP Paribas Financial Markets first reported a position in NeuroSense Therapeutics in Q2 2025 and held it in 1 quarter.
  • BNP Paribas Financial Markets's NeuroSense Therapeutics position peaked at $12.9K in Q2 2025.
  • 10 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q3 2025, filed 13 Nov 2025.